AVEO Pharmaceuticals Company Profile (NASDAQ:AVEO)

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AVEO
  • CUSIP: 05358810
  • Web: www.aveopharma.com
Capitalization:
  • Market Cap: $91.93 million
  • Outstanding Shares: 110,362,000
Average Prices:
  • 50 Day Moving Avg: $0.61
  • 200 Day Moving Avg: $0.66
  • 52 Week Range: $0.50 - $1.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.38
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.84 million
  • Price / Sales: 23.94
  • Book Value: $0.04 per share
  • Price / Book: 18.93
Profitability:
  • EBIDTA: ($29,880,000.00)
  • Net Margins: -465.54%
  • Return on Equity: -286.18%
  • Return on Assets: -74.75%
Debt:
  • Debt-to-Equity Ratio: 3.71%
  • Current Ratio: 5.00%
  • Quick Ratio: 5.00%
Misc:
  • Average Volume: 537,710 shs.
  • Beta: 0.97
  • Short Ratio: 3.84
 

Frequently Asked Questions for AVEO Pharmaceuticals (NASDAQ:AVEO)

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.00. The company earned $2.53 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 286.18% and a negative net margin of 465.54%. View AVEO Pharmaceuticals' Earnings History.

Where is AVEO Pharmaceuticals' stock going? Where will AVEO Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 1 year target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $3.00 in the next twelve months. View Analyst Ratings for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 1,202,176 shares, an increase of 48.6% from the March 31st total of 809,125 shares. Based on an average trading volume of 617,198 shares, the short-interest ratio is presently 1.9 days. Approximately 1.5% of the shares of the stock are sold short.

Who are some of AVEO Pharmaceuticals' key competitors?

Who owns AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include GROWTH EQUITY OPPORTUNITIES IV, LLC (23.00%), NEA Management Company LLC (0.00%), Perceptive Advisors LLC (4.63%), Sphera Funds Management LTD. (0.00%), Renaissance Technologies LLC (0.00%) and Vanguard Group Inc. (0.00%). View Institutional Ownership Trends for AVEO Pharmaceuticals.

Who sold AVEO Pharmaceuticals stock? Who is selling AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Vanguard Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for AVEO Pharmaceuticals.

Who bought AVEO Pharmaceuticals stock? Who is buying AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Sphera Funds Management LTD., Perceptive Advisors LLC, Sabby Management LLC, Paloma Partners Management Co and Geode Capital Management LLC. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy AVEO Pharmaceuticals stock?

Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AVEO Pharmaceuticals stock cost?

One share of AVEO Pharmaceuticals stock can currently be purchased for approximately $0.83.

Analyst Ratings

Consensus Ratings for AVEO Pharmaceuticals (NASDAQ:AVEO) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (260.14% upside)

Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
6/16/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Earnings History by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.12)($0.12)$2.53 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.12)($0.07)$0.99 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)
2017 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.08)($0.08)($0.08)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 37.94%
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.20View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AVEO Pharmaceuticals (NASDAQ:AVEO)
Latest Headlines for AVEO Pharmaceuticals (NASDAQ:AVEO)
Source:
DateHeadline
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 23 at 1:16 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - May 22 at 11:30 AM
finance.yahoo.com logoAVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma
finance.yahoo.com - May 19 at 9:21 AM
wsj.com logoCFO Moves: AVEO Pharmaceuticals, Community Health Systems
blogs.wsj.com - May 18 at 12:01 PM
reuters.com logoBRIEF-Aveo appoints Matthew Dallas chief financial officer
www.reuters.com - May 16 at 12:28 PM
finance.yahoo.com logoAVEO Announces Appointment of Matthew Dallas as Chief Financial Officer
finance.yahoo.com - May 16 at 12:28 PM
finance.yahoo.com logoAVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer
finance.yahoo.com - May 15 at 4:13 PM
finance.yahoo.com logoAVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353
finance.yahoo.com - May 8 at 10:43 AM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
finance.yahoo.com - May 5 at 8:48 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Announces Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM
finance.yahoo.com logoAVEO Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 4 at 8:49 PM
marketbeat.com logoAVEO reports 1Q loss
marketbeat.com - May 4 at 9:12 AM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Getting Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 1:01 AM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Receives Daily News Sentiment Score of 0.04
www.americanbankingnews.com - April 30 at 1:33 PM
americanbankingnews.com logoShort Interest in AVEO Pharmaceuticals, Inc. (AVEO) Expands By 48.6%
www.americanbankingnews.com - April 28 at 7:24 AM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 4:42 PM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Down 17.4% Since Earnings Report: Can It Rebound? - Yahoo Finance
finance.yahoo.com - April 24 at 3:44 PM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Earns Coverage Optimism Score of -0.12
www.americanbankingnews.com - April 24 at 2:21 PM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Down 17.4% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 24 at 10:28 AM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Receives News Sentiment Score of 0.44
www.americanbankingnews.com - April 21 at 11:35 AM
finance.yahoo.com logoAVEO Announces Presentations at the 2017 ASCO Annual Meeting
finance.yahoo.com - April 20 at 3:50 PM
americanbankingnews.com logo-$0.13 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
www.americanbankingnews.com - April 19 at 12:14 AM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Receiving Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 18 at 12:19 PM
seekingalpha.com logoAre We Hearing AVEO Pharmaceuticals' Death Rattle? - Seeking Alpha
seekingalpha.com - April 17 at 3:40 PM
seekingalpha.com logoAre We Hearing AVEO Pharmaceuticals' Death Rattle? - Seeking Alpha
seekingalpha.com - April 17 at 3:40 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Rating Reiterated by FBR & Co
www.americanbankingnews.com - April 17 at 1:14 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 15 at 7:44 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Likely to Impact AVEO Pharmaceuticals (AVEO) Share Price
www.americanbankingnews.com - April 14 at 5:20 PM
reuters.com logoBRIEF-Aveo announces submission of response to Tivozanib marketing authorization application day 180 list of outstanding issues
www.reuters.com - April 13 at 3:55 PM
finance.yahoo.com logoAVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues
finance.yahoo.com - April 13 at 3:55 PM
us.rd.yahoo.com logoAVEO Announces Milestone Payment from CANbridge for AV-203
us.rd.yahoo.com - April 3 at 4:07 PM
businesswire.com logoAVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Business Wire (press release)
www.businesswire.com - March 31 at 8:53 PM
finance.yahoo.com logoAVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - March 31 at 8:53 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Equity Opportunities Iv Growth Buys 6,000,000 Shares
www.americanbankingnews.com - March 29 at 7:13 PM
biz.yahoo.com logoAVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat
biz.yahoo.com - March 29 at 12:46 PM
reuters.com logoBRIEF-Aveo announces proposed offering of common stock
www.reuters.com - March 28 at 3:44 PM
finance.yahoo.com logoAVEO PHARMACEUTICALS INC Financials
finance.yahoo.com - March 28 at 3:44 PM
streetinsider.com logoAVEO Oncology (AVEO) Confirms Proposed Offering of Common Stock; Proceeds to Support Tivozanib Development
www.streetinsider.com - March 28 at 11:38 AM
reuters.com logoBRIEF-Aveo announces pricing of $15 mln public offering of common stock
www.reuters.com - March 28 at 11:38 AM
finance.yahoo.com logoAVEO Announces Proposed Offering of Common Stock
finance.yahoo.com - March 28 at 11:38 AM
finance.yahoo.com logoAVEO Announces Pricing of $15.0 Million Public Offering of Common Stock
finance.yahoo.com - March 28 at 11:38 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:34 PM
americanbankingnews.com logoAnalysts Offer Predictions for AVEO Pharmaceuticals, Inc.'s Q1 2017 Earnings (AVEO)
www.americanbankingnews.com - March 27 at 9:46 AM
americanbankingnews.com logoFBR & Co Comments on AVEO Pharmaceuticals, Inc.'s FY2021 Earnings (AVEO)
www.americanbankingnews.com - March 24 at 2:28 PM
zacks.com logoAVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
www.zacks.com - March 23 at 4:09 PM
reuters.com logoBRIEF-Aveo Pharmaceuticals says doubts ability to continue as a going concern - SEC filing
www.reuters.com - March 22 at 9:28 PM
biz.yahoo.com logoAVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - March 22 at 9:28 PM
reuters.com logoBRIEF-Aveo announces first patient dosed in phase 1/2 tinivo trial
www.reuters.com - March 22 at 4:15 PM
finance.yahoo.com logoAVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
finance.yahoo.com - March 22 at 4:15 PM
finance.yahoo.com logoAVEO Reports Full Year 2016 Financial Results and Provides Business Update
finance.yahoo.com - March 22 at 4:15 PM

Social

Chart

AVEO Pharmaceuticals (AVEO) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff